維奈妥拉|T2119|TargetMol

1篇文獻(xiàn)

價(jià)格	￥495	￥695	￥895
包裝	5mg	10mg	50mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-02

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:維奈妥拉	英文名稱:Venetoclax
CAS:1257044-40-8	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 99.96%	產(chǎn)品類別: 抑制劑
貨號(hào): T2119

Product Introduction

Bioactivity

名稱	Venetoclax
描述	Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.
細(xì)胞實(shí)驗(yàn)	RS4;11 cells were seeded at 50,000 per well in 96-well plates and treated with compounds diluted in half-log steps starting at 1 μM and ending at 0.00005 μM. All other leukemia and lymphoma cell lines were seeded at 15,000–20,000 cells per well in the appropriate medium and incubated with ABT-199 or navitoclax for 48 h. Effects on proliferation were determined using Cell TiterGlo reagent. EC50 values were determined by nonlinear regression analysis of the concentration-response data. Mouse FL5.12–BCL-2 and FL5.12–BCL-XL cells were propagated and assessed as described previously. Bak?/? Bax?/? double knockout mouse embryonic fibroblasts were seeded into 96-well microtiter plates at 5,000 cells per well in DMEM supplemented with 10% FBS. ABT-199 in the same culture medium was added in half-log dilutions starting at 5 μM. The cells were then incubated at 37 °C (5% CO2) for 48 h, and the effects on proliferation were determined using Cell TiterGlo reagent according to the manufacturer's instructions [1].
激酶實(shí)驗(yàn)	The equilibrium binding experiments of fluorescent peptides to Bcl-xL protein were performed in an Analyst 96-well plate reader under the following conditions: each individual well in a 96-well assay plate contained 5 μl DMSO, 15 nM fluorescent peptide, and increasing concentrations (from 0 to 2.24 μM) of Bcl-xL protein in assay buffer in a final volume of 125 μl. The plate was mixed on a shaker for 1 min and incubated at room temperature for an additional 15 min. The polarization in millipolarization units (mP) was measured at room temperature with an excitation wavelength at 485 nm and an emission wavelength at 530 nm. For assay stability testing, a plate containing a binding experiment was measured at different times over a 24-h period. Between each reading, the plate was covered with parafilm to prevent any solution evaporation. To determine the effect of DMSO on the assay, binding experiments were performed under conditions similar to those described above except that the amount of DMSO was varied from 0 to 4 to 8%. All experimental data were analyzed using Prism 3.0 software and Kd values were generated by fitting the experimental data using a sigmoidal dose-response nonlinear regression model [1].
動(dòng)物實(shí)驗(yàn)	Female C.B-17 SCID mice (DoHH2 and Granta-519 xenografts) and female C.B-17 SCID-beige mice (RS4;11 and Toledo xenografts) were inoculated with 1 × 10^6 (DoHH2) or 5 × 10^6 (Granta-519, Toledo and RS4;11) cells subcutaneously in the right flank. The inoculation volume (0.2 ml) comprised a 50:50 mixture of cells in growth media and Matrigel. Electronic calipers were used to measure the length and width of each tumor 2–3 times per week. Tumor volume was estimated by applying the following equation: volume = length × width2/2. When tumors reached approximately 220 mm3, mice were size matched (day 0) into treatment and control groups. All xenograft trials were conducted using ten mice per group, and all mice were ear tagged and monitored individually throughout the studies. ABT-199 was formulated for oral dosing in 60% phosal 50 propylene glycol (PG), 30% polyethylene glycol (PEG) 400 and 10% ethanol, and bendamustine and rituximab were formulated in accordance with the manufacturer's instructions. ABT-199 was delivered approximately 2 h before bendamustine or bendamustine plus rituximab. TGImax was calculated as the greatest treatment response using the following equation: TGImax = (1 ? mean tumor volume of the treated group/mean tumor volume of the vehicle control group) × 100. The TGD (%) was determined as the percentage increase of the median time period for the treatment group to reach an arbitrary tumor volume of 1,000 mm3 relative to the vehicle control group. A complete tumor regression response was the portion of the population with tumors ≤25 mm3 for at least three consecutive measurements [1].
體外活性	方法：11 種人 T 細(xì)胞急性淋巴細(xì)胞白血病細(xì)胞 T-ALL 用 Venetoclax (0-12 μM) 處理 48 h，使用 Celltiter-Glo Luminescent Cell Viability Assay 檢測(cè)細(xì)胞活力。結(jié)果：Venetoclax 對(duì) 11 種 T-ALL 的 IC50 值范圍為 0.2-10 μM。[1] 方法：人急性淋巴白血病細(xì)胞 RS4;11 用 Venetoclax (0.01-5 μM) 孵育 3.5 h，使用 Caspase-GLO kit 評(píng)估 Caspase-3/7 活性。結(jié)果： Venetoclax 誘導(dǎo) Caspase 的激活，這是細(xì)胞凋亡特征之一。[2] 方法：人原代 HCL 白血病細(xì)胞用 Venetoclax (0.1-1 μM) 處理 24 h，使用 Flow Cytometry 方法檢測(cè)細(xì)胞死亡情況。結(jié)果：Venetoclax 以劑量依賴的方式顯著增加了 HCL 細(xì)胞的細(xì)胞死亡。[3]
體內(nèi)活性	方法：為檢測(cè)體內(nèi)抗腫瘤活性，將 Venetoclax (100 mg/kg in 60% PG+30% PEG 400+10% ethanol) 口服給藥給攜帶人彌漫大B細(xì)胞淋巴瘤 Toledo 的 C.B-17 SCID-beige 小鼠，每天一次，持續(xù)二十一天。結(jié)果：Venetoclax 可顯著抑制 Toledo 腫瘤的生長(zhǎng) (TGImax=93%，TGD=220%)。[2] 方法：為檢測(cè)體內(nèi)抗腫瘤活性，將 Venetoclax (50 mg/kg in 10% ethanol+30% PEG 400+60% Phosal 50PG，口服給藥，每天一次) 和 anti-PD-1 (10 mg/kg in PBS，腹腔注射，每四天三次) 給藥給攜帶小鼠結(jié)直腸癌腫瘤 MC38 的 C57BL/6 小鼠，持續(xù)十四天。結(jié)果：Venetoclax 可以增強(qiáng)免疫檢查點(diǎn)抑制劑 (ICIs) 的抗腫瘤功效，同時(shí)增加 PD-1+T 效應(yīng)記憶細(xì)胞。Venetoclax 在體外對(duì)抗原刺激的反應(yīng)中不會(huì)損害人類 T 細(xì)胞的功能，也不會(huì)拮抗 anti-PD-1 誘導(dǎo)的 T 細(xì)胞活化。[4]
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 100 mg/mL (115.15 mM)
關(guān)鍵字	bioavailable \| GDC0199 \| orally \| inhibit \| Inhibitor \| Bcl-2 Family \| GDC 0199 \| Venetoclax \| Autophagy
相關(guān)產(chǎn)品	Guanidine hydrochloride \| Naringin \| Valproic Acid \| Taurine \| Gefitinib \| Aceglutamide \| Hydroxychloroquine \| Curcumin \| Stavudine \| Salicylic acid \| Paeonol \| Sodium 4-phenylbutyrate
相關(guān)庫(kù)	抑制劑庫(kù) \| 抗癌活性化合物庫(kù) \| 抗癌上市藥物庫(kù) \| 已知活性化合物庫(kù) \| EMA 上市藥物庫(kù) \| 高選擇性抑制劑庫(kù) \| FDA 上市藥物庫(kù) \| 藥物功能重定位化合物庫(kù) \| 抗癌臨床化合物庫(kù) \| 抗癌藥物庫(kù)

關(guān)鍵字：維奈妥拉|||GDC-0199|||ABT-199|||ABT199|||ABT 199|TargetMol

公司簡(jiǎn)介

上海陶術(shù)生物科技有限公司為美國(guó)Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國(guó)波士頓、德國(guó)慕尼黑的同事一起，為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部，化學(xué)事業(yè)部，生物事業(yè)部和新材料部。從虛擬篩選到實(shí)體化合物分子供應(yīng)；從商業(yè)化產(chǎn)品銷售到個(gè)性化定制合成；從對(duì)明確靶點(diǎn)的分子篩選到對(duì)明確分子的多靶點(diǎn)篩選，從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化，我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。經(jīng)過(guò)在中國(guó)市場(chǎng)五年的精心耕耘，我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商，為超過(guò)五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩

成立日期	2013-04-18 （12年）	注冊(cè)資本	566.2651萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	化學(xué)試劑,生物活性小分子	經(jīng)營(yíng)模式	貿(mào)易,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 12年

公司成立：12年
注冊(cè)資本：566.2651萬(wàn)人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑，藥物篩選化合物庫(kù)，天然產(chǎn)物，活性分子化合物等
公司地址：上海市閘北區(qū)江場(chǎng)三路28號(hào)4樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

甲磺酸卡莫司他|T2391|TargetMol

￥198

?；敲撗跄懰徕c|TN2349|TargetMol

￥418

對(duì)甲氧基苯甲酸|TCS0862|TargetMol

￥210